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Introduction: Acute kidney injury (AKI) is a common and feared complication of sepsis. The pathogenesis of
sepsis-induced AKI is largely unknown, and therapeutic interventions are mainly supportive. In the present study,
we tested the hypothesis that pharmacological inhibition of Toll-like receptor 4 (TLR4) would improve renal function
and reduce renal damage in experimental sepsis, even after AKI had already developed.
Methods: Sheep were surgically instrumented and subjected to a 36-hour intravenous infusion of live Escherichia
coli. After 12 hours, they were randomized to treatment with a selective TLR4 inhibitor (TAK-242) or vehicle.
Results: The E. coli caused normotensive sepsis characterized by fever, increased cardiac index, hyperlactemia,
oliguria, and decreased creatinine clearance. TAK-242 significantly improved creatinine clearance and urine output.
The increase in N-acetyl-beta-D-glucosaminidas, a marker of tubular damage, was attenuated. Furthermore, TAK-242
reduced the renal neutrophil accumulation and glomerular endothelial swelling caused by sepsis. These effects
were independent of changes in renal artery blood flow and renal microvascular perfusion in both cortex and
medulla. TAK-242 had no effect per se on the measured parameters.
Conclusions: These results show that treatment with a TLR4 inhibitor is able to reverse a manifest impairment in
renal function caused by sepsis. In addition, the results provide evidence that the mechanism underlying the effect
of TAK-242 on renal function does not involve improved macro-circulation or micro-circulation, enhanced renal
oxygen delivery, or attenuation of tubular necrosis. TLR4-mediated inflammation resulting in glomerular endothelial
swelling may be an important part of the pathogenesis underlying Gram-negative septic acute kidney injury.Introduction
Acute kidney injury (AKI) is an important contributor to
morbidity and mortality among hospitalized patients.
Sepsis is the leading cause of AKI in the critically ill pa-
tient, and currently no effective treatment exists [1].
Septic AKI is generally believed to be due to regional hy-
poperfusion causing renal ischemia [2]. However, recent
experimental reports indicate that AKI may develop
even though renal blood flow and blood pressure remain
within physiological limits [3-5]. Thus, it is possible that
the pathogenesis of septic AKI is complicated by factors
other than ischemia. In line with this, we wanted to* Correspondence: robert.frithiof@surgsci.uu.se
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article, unless otherwise stated.investigate whether an important receptor for initiating
inflammation, the Toll-like receptor 4 (TLR4), partici-
pates in the pathophysiology of Escherichia coli-induced
AKI. TLRs have been identified as pivotal mediators in
host defense as they are crucial in pathogen recognition
and activation of the immune response [6,7]. The main
ligand for TLR4 is lipopolysaccharide (LPS), a compo-
nent of the cell membrane of Gram-negative bacteria
[8-10]. When LPS binds to TLR4, an inflammatory re-
sponse is initiated via production and release of cyto-
kines as well as stimulation of inflammatory cells [11].
Targeting TLR4 with antibodies or specific inhibitors has
shown beneficial effects by reducing mortality in experi-
mental models of Gram-negative sepsis [12-17]. Initial
clinical trials also showed beneficial effects of blocking
TLR4 in sepsis [18], but in larger follow-up investiga-
tions, survival was not improved [19,20]. However, the
renal effects of TLR4 antagonism are incompletelyntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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may be an important mediator of sepsis-induced AKI.
For example, the expression of TLR4 in renal tubules,
glomeruli, and peri-tubular capillaries is increased after
sepsis [21], and mice deficient in TLR4 have a reduced
increase in blood urea nitrogen (BUN) when subjected
to LPS [22]. Our group recently showed that pre-
treatment with TAK-242 attenuated oliguria and reduced
creatinine clearance in LPS-induced hyperdynamic shock
[3]. However, although the aforementioned results are
promising, the potential of TLR4 modulation during sepsis
and septic renal failure, as well as mechanisms of action, is
still largely unknown.
One of the main objectives with the current study was
to investigate whether TLR4 inhibition is effective in at-
tenuating or reversing renal dysfunction even after sepsis
has developed. Therefore, TAK-242 was administered
12 hours into normotensive ovine sepsis caused by an
intravenous live E. coli infusion, and the effect on renal
function was followed for an additional 24 hours. To fur-
ther explore the hypothesis that septic AKI is due to re-
gional blood flow restriction, total renal blood flow and
cortical and medullary microcirculation were continu-
ously measured. Signs of ischemia were repeatedly moni-
tored by microdialysis in the cortex and medulla. It is
highly debatable whether septic AKI is associated with
renal histopathology, and studies investigating structural
damage to the kidney in long-term animal model of sep-
sis are lacking [23]. Thus, both light and electron mi-
croscopy were used to analyze renal samples taken at
the end of the 36-hour study period with regard to local
injury and leukocyte infiltration.
Materials and methods
For detailed description of methods, please refer to the on-
line supplemental material (Additional file 1). The experi-
ments conform to the guidelines laid out in the Guide for
the Care and Use of Laboratory Animals (National Acad-
emy of Science). The Regional Ethics Committee for Ex-
periments in Animals, Stockholm, Sweden, approved the
study in advance (N285/08).
Surgical preparation and study protocol
Twenty-seven adult Texel crossbred ewes were included
in the study. Twenty-four of these sheep were anesthe-
tized and prepared with catheters in the right carotid ar-
tery, the pulmonary artery, and the right jugular vein.
For renal hemodynamic measurements, an ultrasonic
flow probe was placed around the left renal artery, and
two laser Doppler flow probes, one cortical and one
medullar, were sutured on the left kidney. Intrarenal me-
tabolism was studied by microdialysis catheters in the
cortex and in the medulla, respectively. A urinary reten-
tion catheter was inserted into the bladder for urinesampling. After a post-surgical recovery period of 12 to
18 hours, the experiments commenced with the animals
being conscious and placed in a pen. Sepsis was induced
by an intravenous infusion of live E. coli bacteria (bolus
of 3.9 × 109 colony-forming units followed by an infusion
of 6.0 × 109/mL colony-forming units, starting at a rate of
0.2 mL/hour). The infusion rate was increased stepwise
every 6 hours until reaching 4 mL/hour after 30 hours.
After 12 hours of sepsis, sheep were randomized to re-
ceive a bolus dose (2 mg/kg) followed by a continuous
infusion (4 mg/kg per 24 hours) of either the selective
TLR4 inhibitor TAK-242 (10 mg/mL) (n = 7) or vehicle
(n = 7). The treatment was blinded to the investigators,
and the content of the infusions was revealed only after
the experiments were performed. To exclude that surgery
per se had a major impact on the results obtained in the
TAK-242 and vehicle groups, an additional sheep served
as time control. This included surgical preparation and re-
covery and monitoring for 36 hours but no E. coli infusion
or treatment.
To investigate whether TAK-242 had any effect on
renal function per se, an additional three sheep were
surgically prepared and, in a cross-over design, sub-
jected to treatment with either TAK-242 or vehicle. The
treatment was initiated by a bolus dose (2 mg/kg) followed
by a continuous infusion (2 mg/kg per 12 hours). No
E. coli was administered.
Besides the intravenous fluids given post-surgery, fluid
volume support was administered as Ringer’s Acetate so-
lution (B. Braun Melsungen, AG, Melsungen, Germany)
intravenously at 1 mL/kg per hour and started 6 hours
before the infusion of live E. coli bacteria. Blood samples
(approximately 20 mL of venous blood and 1 mL of ar-
terial blood) were drawn at baseline and every 6 hours
after commencement of sepsis. Urinary output was mea-
sured and urine samples were collected every second
hour. After 36 hours of sepsis, animals were deeply
anaesthetized with sodium thiopental and terminated by
an overdose of potassium chloride. The kidney was rap-
idly harvested and prepared for histological evaluation.
The position of the laser Doppler probes and microdial-
ysis catheters was confirmed visually by opening the kid-
ney post-mortem. Renal biopsies were immediately
frozen and stored at −70°C. If the animal was judged to
be severely ill and in distress, it was euthanized prior to
the end of the protocol.
Histological evaluation of renal biopsies
Small pieces of renal tissue were prepared and evaluated
by light and transmission electron microscopy. In addition,
some sections were stained with anti-myeloperoxidase
antibody for easy quantification of polymorphonuclear
leukocyte (PMN) cells in the glomeruli, the interstitium,
and the peritubular capillaries.
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Cardiovascular parameters were averaged off-line. Cre-
atinine clearance was calculated as (urine flow × urine
creatinine concentration)/plasma creatinine concentra-
tion. Cardiac output was indexed to body surface area
(0.09 × body weight0.67).
All statistical calculations were performed by using
Statistica 8.0 (Statsoft Inc., Tulsa, OK, USA), and the
graphs were created with Sigma Plot 11.0 (SPSS Inc.,
Chicago, IL, USA). Data are expressed as means ± stand-
ard deviation of the mean or as mean and 95% confi-
dence interval. Urine production, fractional sodium
excretion (FENa), and urinary-N-acetyl-beta-D-glucosa-
minidase (U-NAG) values were transformed to follow a
normal distribution by taking the logarithm of the raw
data. Changes in parameters over time were analyzed
according to a two-way repeated measures analysis of
variance (ANOVA), with time as within effects and treat-
ment (control/TAK-242) as between effects. If there was
a significant interaction between time × treatment, an
additional one-way repeated measures ANOVA was per-
formed for each treatment to investigate whether that
group changed significantly over time. The result of this
analysis is not displayed in the figures but is referred to
in the Results section. The significance level was set at a
P value of not more than 0.05. Mann-Whitney U test
was used to evaluate difference in PMN count and histo-
logical scores between treatments.
Results
Nine out of twenty-three sheep subjected to E. coli had
to be euthanized before completion of the protocol: five
before treatment was started as well as two TAK-242-
treated animals and two vehicle-treated animals be-
tween 12 and 14 hours of sepsis. These sheep are not
included in the data presented in the figures/tables or
the statistical analyses. No effect of surgery per se was
seen in the sheep that was sham-operated (Additional
file 2: Table S3).
E. coli infusion caused hyperdynamic sepsis
Intravenous infusion of live E. coli bacteria caused
classic signs of hyperdynamic sepsis; tachycardia, pul-
monary hypertension, increased cardiac index, and a de-
crease in systemic vascular resistance (Figure 1A-C and
F, P <0.05 for all). However, mean arterial blood pres-
sure remained close to baseline levels, indicating that
the animals were not in shock (Figure 1E). TAK-242 at-
tenuated the increase in mean pulmonary arterial pres-
sure (MPAP) but had no significant effect on any other
of these variables (Figure 1). Arterial levels of lactate in-
creased as a response to sepsis. However, in parallel
with an improved renal function, TAK-242 reversed this
trend and reduced lactate levels to near baseline values(Figure 1D). Treatment with TAK-242 attenuated the
decline in arterial partial pressure of oxygen (pO2)
caused by sepsis and it ended significantly higher com-
pared with the control group. Partial pressure of carbon
dioxide (pCO2) increased in both groups without inter-
group difference. No significant change over time or dif-
ference between the groups was observed in arterial pH,
base excess, hematocrite, plasma protein, sodium, or
potassium levels (Additional file 3: Table S1). Sepsis in-
duced nitric oxide (NO) formation as indicated by in-
creased plasma levels of NOx (sum of nitrite and
nitrate) and cyclic guanosine monophosphate (P <0.05
for both) with no effect of treatment with TAK-242.
NOx in urine did not change significantly during the ex-
periment (Additional file 3: Table S1).
Sepsis-induced renal dysfunction was reversed by the
TLR4 inhibitor TAK-242
After 12 hours of sepsis, renal function was reduced as
measured by elevated plasma levels of creatinine and
BUN, together with a decrease in creatinine clearance,
urine production, and filtration fraction (Figure 2A-E,
P <0.05 for all). The TLR4 inhibitor had a clear benefi-
cial effect on renal function: Urine production de-
creased progressively in the control group, reaching
severe oliguria in all animals, but TAK-242 not only
prevented this decline but also improved diuresis sig-
nificantly between 12 and 36 hours (P <0.01, Figure 2A).
Furthermore, treatment with TAK-242 abolished the
impairment in creatinine clearance (Figure 2, P = 0.002)
and attenuated the increase in plasma levels of creatinine,
filtration fraction, and BUN (P <0.05, for all Figure 2).
U-NAG, a marker of tubular damage, was significantly
elevated at the end of the experiment, but TAK-242 at-
tenuated this increase (P <0.05, Figure 2F), indicating
less tubular injury in sheep with TLR4 inhibition.
Sepsis did not cause renal hypoperfusion
A possible explanation for the beneficial effects of TAK-
242 was prevention of renal hypoperfusion. However,
renal artery blood flow increased (P <0.001) during sep-
sis and renal vascular resistance was significantly de-
creased (P <0.001) without any intergroup differences
(Figure 3). This was mirrored as an increased perfusion
in the renal cortex (P <0.05), but medullary perfusion
remained close to baseline levels in both groups (Figure 3).
Light microscopy revealed no obvious renal tubular dam-
age that explained the renal dysfunction. The tubules
appeared normal except in two of the vehicle animals,
where areas of proximal tubular injury were seen within
the cortex (Figure 4). In such areas, the epithelial cells
showed pyknotic or disintegrated nuclei (Figure 4D) or
isometric vacuolization of the cytoplasm or both. In one
of the TAK-242-treated animals, similar but much milder





























































































































Figure 1 Changes in cardiac index (A), heart rate (B), mean pulmonary arterial pressure (MPAP) (C), arterial lactate (D), mean arterial
blood pressure (MAP) (E), and systemic vascular resistance (SVR) (F) in response to sepsis and treatment with either the selective TLR4
inhibitor TAK-242 (n = 7) or vehicle (n = 7). Data are expressed as mean and 95% confidence interval. Asterisk indicates a significant difference
between TAK-242 and control in response to sepsis. Analysis of variance (ANOVA) repeated measures from 12 to 36 hours.
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In two of the vehicle animals, fibrin thrombi were found
in the glomerular capillaries (Additional file 4: Figure S1).
Treatment with a TLR4 inhibitor attenuated septic renal
hyperlactemia
To measure renal metabolic changes, microdialysis
probes were placed in the renal cortex and medulla.
During the first 12 hours of sepsis lactate, pyruvate and
the lactate/pyruvate (L/P) ratio increased in both the
cortex and the medulla whereas glucose was not signifi-
cantly altered (Additional file 5: Table S2). TAK-242 sig-
nificantly attenuated the increase in lactate (Additional
file 5: Table S2) and reduced the L/P ratio (Figure 3) in
both cortex and medulla. However, glucose and pyruvate
levels remained stable, and no effect of treatment was
observed (Additional file 5: Table S2).
Treatment with a TLR4 inhibitor reduced renal neutrophil
infiltration
In the vehicle- and TAK-242-treated groups, increased
amounts of PMN cells were found in the glomeruli andthe interstitium/peritubular capillaries compared with
controls. This was confirmed by quantification of PMNs
by using immunohistochemistry (Figure 5). Compared
with vehicle, TAK-242 significantly reduced the number
of PMNs in the interstitium (P = 0.01, Figure 6A) but
not in the glomerulus (P = 0.16, Figure 6B).
Sepsis-induced endothelial swelling and decreased
fenestration in the glomeruli were attenuated by a TLR4
inhibitor
To examine the glomerular effects of sepsis and subse-
quent treatment with a TLR4 inhibitor, electron micros-
copy was used. There was no difference in the degree
of foot process effacement or in the thickness of the
glomerular basement membrane (GBM) between the
vehicle-treated (232 ± 29 nm), TAK-242-treated (264 ±
72 nm), and sham (242 ± 9 nm) groups (Figure 7). How-
ever, there was a difference in the ultrastructure of the
endothelial cells in the glomerular capillaries. The endo-
thelial cells of the vehicle-treated animals were more
swollen (P = 0.03, Figures 6C and 7) and showed a ten-
dency for decreased fenestration (P = 0.07, Figures 6D
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Figure 2 Changes in diuresis (A), creatinine clearance (Crea Clear) (B), filtration fraction (C), blood urea nitrogen (BUN) (D) plasma
creatinine (P-Crea) (E), and urinary concentrations of N-acetyl-ß-D-glucosaminidase (U-NAG) (F) in response to sepsis and treatment
with either the selective TLR4 inhibitor TAK-242 (n = 7) or vehicle (n = 7). Data are expressed as mean and 95% confidence interval. Asterisk
indicates a significant difference between TAK-242 and control in response to sepsis. Analysis of variance (ANOVA) repeated measures from 12
to 36 hours.
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sham. Furthermore, the light microscopic observation of
fibrin thrombi was confirmed in the two vehicle-treated
animals (Additional file 4: Figure S1).
TAK-242 had no effect per se
There were no obvious differences in MAP, HR, CI, or
MPAP between TAK-242 and vehicle during the 12-
hour treatment period in healthy sheep (Additional file
6: Figure S2). Renal function, as evaluated by creatinine
clearance, plasma clearance, BUN, and urine output,
remained stable, and no difference between treatments
was seen (Additional file 7: Figure S3). Finally, renal
blood flow and blood gas parameters remained un-
affected by TAK-242 per se (Additional file 7: Figure S3
and Additional file 8: Table S4).
Discussion
In the present study, we aimed to investigate the renal
effects of a TLR4-inhbitor, TAK-242, in experimentalsepsis. The most striking finding was that TAK-242 re-
versed a progressive decline in renal function when ad-
ministered therapeutically after 12 hours of hyperdynamic
E. coli sepsis. This was associated with a prominent reduc-
tion in renal neutrophil infiltration, a decreased swelling
of the endothelium in the glomerular capillaries, an at-
tenuation of arterial and renal hyperlactemia, and less
tubular damage as indicated by reduced U-NAG. Fur-
thermore, no major effects on systemic or local renal
hemodynamics by TAK-242 were seen during sepsis,
and in separate experiments in animals without sepsis,
TAK-242 had no obvious major effects per se.
Proper animal models of septic AKI are difficult to
achieve, and too often they do not mimic the clinical
scenario [24]. In this study, we used fluid-resuscitated,
conscious animals developing severe hyperdynamic sep-
sis caused by live bacteria. Detailed renal functional data
were collected repeatedly over an extended time period
and related to immune function and histological path-
ology. In addition, treatment was started when sepsis and
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Figure 3 Changes in renal artery blood flow (RBF) (A), laser Doppler changes in renal cortex (LD Cortex) (B), laser Doppler changes in
renal medulla (LD Medulla) (C), renal vascular resistance (RVR) (D), lactate/pyruvate ratio in cortex (L/P Cortex) (E), and lactate/
pyruvate ratio in medulla (L/P Medulla) (F) in response to sepsis and treatment with either the selective TLR4 inhibitor TAK-242 (n = 7)
or vehicle (n = 7). Data are expressed as mean and 95% confidence interval. Asterisk indicates a significant difference between TAK-242 and
control in response to sepsis. Analysis of variance (ANOVA) repeated measures from 12 to 36 hours.
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of this investigation was that the renal histological findings
in large mimicked what was recently described in human
kidney after sepsis [6].
Innate immunity is the first line of defense against in-
vading microbes and is crucial for preventing infections.
TLR4 is central in this immune activation by binding
LPS [9,25], which results in an inflammatory response
that induces the production and release of cytokines
as well as stimulation of inflammatory cells [11]. Among
these cells are neutrophils, which are activated and stimu-
lated to transmigrate from blood to tissue. This is caused
by TLR4-mediated release of interleukin-1B (IL-1B),
tumor necrosis factor-alpha (TNFα), and IL-6. Another
important neutrophil activator released by TLR4 stimula-
tion is serum amyloid protein 3, which mediates its effect
by targeting the formyl peptide receptor [26]. Although
the inflammatory response is crucial for preventing infec-
tions, a strong activation of the innate immune system,
like in sepsis, may inflict damage to endogenous tissueand impair organ function. TAK-242 binds selectively to
the intracellular domain of TLR4 and disrupts the inter-
action with several adaptor molecules. This leads to inhib-
ition of both the MyD88-dependent and the TRIF (TIR
domain-containing adapter-inducing IFN-β)-dependent
pathway for TLR4 signal transduction [27].
Acute tubular necrosis (ATN) caused by ischemia has
been assumed to be the underlying pathophysiology of
septic AKI [2,28]. Massive release of NO is believed to
cause vasodilation that result in relative hypovolemia, a
reduction in cardiac output, and hypotension. As a re-
flex, renal sympathetic nerve activity is increased to-
gether with elevated levels of vasopressin, endothelin,
angiotensin II, and aldosterone. The resulting renal vas-
cular vasoconstriction leads to ischemia and subsequent
ATN that impairs renal function. Undoubtedly, ischemia
is a crucial factor for many types of AKI. However, in
sepsis, the situation may sometimes be different. Most
patients with sepsis present with a hyperdynamic circu-
lation with elevated cardiac output [29]. Experimental
Figure 4 Increased renal neutrophil infiltration is attenuated by TLR4 inhibition. Light microscopy with hematoxylin/eosin staining shows
an increased number of polymorphonuclear leukocytes (PMNs) (arrows) in the glomeruli and within the interstitium/peritubular capillaries in
both vehicle-treated (C) and TAK-242-treated (B) animals in comparison with sham (A). Tubular epithelial injury was seen with pyknotic and
disintegrated nuclei in two of the vehicle-treated animals—(C) white arrow and (D) arrows—and one of the TAK-242-treated animals.
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blood flow is increased [4,23] and hypotension is coun-
teracted by vasoactive drugs [3]. Furthermore, the cor-
relation between ATN and septic renal failure is weak
in both human and animal studies [30]. The current
results obtained in normotensive septic sheep confirm
that hypotension is not a necessary attribute for septic
AKI. This is in line with studies in critically ill patients
with severe sepsis, in whom blood pressure levels
did not correlate with the severity of renal failure [31].
TAK-242 drastically improved renal function without
major hemodynamic effects. Moreover, there was no sign
of renal vasoconstriction, as total renal artery blood
flow as well as cortical and medullary perfusion did not
decline during the 36-hour experiment. Thus, renal hy-
poperfusion appears highly unlikely as a cause of septic
AKI, given this experimental setting. A recently pro-
moted hypothesis for sepsis-induced AKI is that the in-
flammatory response causes a preferential dilatation of
renal efferent arterioles, increasing renal blood flow but
reducing the hydrostatic pressure for glomerular filtra-
tion and thereby glomerular filtration rate (GFR) [32].
The most important vasodilator released in sepsis is
NO, and it has been suggested that excessive intra-renalNO could be responsible for the reduction in post-
glomerular resistance [33]. However, it is unlikely that
the effect of TLR4 inhibition on renal function in this
study is mediated by reduced NO formation as there
were no differences in either MAP or renal blood flow
and as TAK-242 did not affect NOx or cyclic guanosine
monophosphate (cGMP) levels. This view is supported
by results demonstrating no effect on renal function
after intrarenal NO synthase inhibition during Gram-
negative sepsis [33].
Both cortical and medullary ratios of L/P were signifi-
cantly increased by sepsis but subsequently reduced by
TAK-242. In view of the preserved renal circulation,
the renal hyperlactemia cannot easily be explained by
reduced renal oxygen supply. However, direct measure-
ment of renal tissue oxygenation or the utilization of
oxygen by renal mitochondria was not performed in
this study. Elevated lactate levels in sepsis not related
to hypoxia have been linked to stimulation of muscle
Na/K-ATPase [34] and mitochondrial dysfunction [35].
Thus, besides hypoxia, other factors may explain the
renal hyperlactemia.
Sepsis caused severe endothelial swelling and decreased
glomerular fenestration, both of which were reduced by
Figure 5 Immunohistochemistry with anti-myeloperoxidase
antibodies show increased number of polymorphonuclear
leukocytes (PMNs) in glomerular capillaries (G) and interstitium/
peritubular capillaries (arrow) in vehicle-treated (B) and
TAK-242-treated (C) group in comparison with sham (A).
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a large extent, be a consequence of decreased glomerular
filtration per se, as creatinine clearance and the filtrationfraction decreased significantly in the vehicle-treated ani-
mals, without significant tubular damage. Endothelial dys-
function in the peritubular capillaries has been highlighted
as an important injury pathway in septic AKI [36], possibly
by inducing ATN [37]. Herein, U-NAG did increase in
vehicle-treated animals as a possible sign of tubular injury,
but this took place several hours after renal function
started to decline and was not confirmed by light micros-
copy. Instead, it is possible that endothelial swelling and
perhaps decreased fenestration in the glomerulus may play
an important role in the injury pathway and propagation
of septic AKI. However, an early and specific marker of
glomerular membrane dysfunction is urine protein leak-
age, and this was not detected in this study and is not a
hallmark of sepsis-induced AKI.
Mobilization and recruitment of PMNs by the innate
immune defense constitute a key event in response to an
infection. After extravasation, PMNs destroy invading
organisms by phagocytosis, release of acid hydrolases
and antimicrobial peptides, and stimulation of antibiotic
actions of monocytes and macrophages [38]. However,
PMN degranulation may also inflict damage to endogen-
ous tissue. The role of PMNs in septic AKI is largely un-
known, but after renal ischemia and reperfusion, PMNs
have been shown to transmigrate from the circulation
and contribute to AKI [39]. In sepsis, Castoldi and col-
leagues [40] recently showed that TLR4-deficient mice
had reduced renal neutrophil activation and infiltration
compared with wild-type mice and that neutrophil
depletion improved renal function. This indicates that
the extensive renal neutrophil accumulation caused by
sepsis in this study is potentially deleterious. Activation
of renal endothelial TLR4 has been suggested to play
a critical role in the upregulation of adhesion mole-
cules which can promote the recruitment of leukocytes
to areas of injury and aggravate damage and inflamma-
tion in the tissue [41,42]. A TLR4-dependent pathway
promoting renal injury and inflammation in antibody-
mediated glomeruli-nephritis and cisplatin-induced
nephrotoxicity has also been described [43,44]. Therefore,
reduced TLR4-dependent infiltration of PMNs may have
contributed to the improved renal function in the TAK-
242 group. This is supported by recent findings of sub-
stantial renal leukocyte infiltration in human septic shock
[6]. Possible mechanisms for the renal dysfunction include
PMN vascular endothelial attachment that reduces blood
flow and causes ischemia [45] or tubular damage by mi-
grated PMNs [46]. However, as discussed previously, no
rheological effects of sepsis or TLR4 inhibition were noted
in the current study, and light microscopy revealed no
convincing evidence of general or widely spread structural
damage to the tubules. Taken together, these observations
indicate that neutrophil activation and recruitment into











































































































Figure 6 Number of polymorphonuclear leukocytes (PMNs) in interstitium (A) and glomerulus (B) as well as histological determination
of endothelial swelling (C) and degree of fenestration in vehicle-treated (D) (n = 7) and TAK-242-treated (n = 7) animals. Zero indicates
no swelling/decreased fenestration, 1 indicates some swelling/decreased fenestration, and 2 indicates severe swelling/decreased fenestration as
determined by electron microscopy. Data are expressed as raw numbers. P <0.05 is considered significant.
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unknown. As shown in a series of elegant experiments by
Watts and colleagues [47-49], TLR4 activation may also
affect renal function by impairing tubular transport. In
particular, HCO3
− reabsorption is inhibited by the direct ef-
fect of LPS on TLR4, and this may contribute to sepsis-
induced acidosis.
Besides renal effects, TLR4 inhibition significantly at-
tenuated the increase in mean pulmonary artery pres-
sure and prevented the decrease in partial pressure of
oxygen. The mechanism for these findings is unknown.
However, a TLR4-dependent pathway for recruitment of
neutrophils into the lung has been highlighted in endo-
toxemic mice [41], and PMN degranulation may cause
severe lung damage [38]. The reason why arterial pCO2
did not change is unknown but may be related to the
fact that CO2, compared with oxygen, more easily dif-
fuses between blood and alveolus.
The current results are partly in contrast to the recent
clinical trial using a TLR4 antagonist in sepsis [19,20]. In
that study, no effect on survival was discovered. How-
ever, data on renal function were not reported, and onlya minority of the patients had verified Gram-negative
sepsis. Thus, it is possible that some patients with sepsis
would still benefit from TLR4 inhibition.
We would like to acknowledge some of the limitations
of this study. Evaluation of the renal microcirculation was
performed with the use of laser Doppler probes surgically
implanted in both the cortex and medulla. This is a well-
established method and is frequently used for assessment
of renal tissue perfusion; however, the technique is inva-
sive, and measurements are performed at a small propor-
tion of the kidney, less than approximately 1 mm3 at each
probe site. Although the technique is a good option for
continuous data acquisition [50], it has problems detecting
heterogeneity in microvascular flow. The use of creatinine
clearance as an indicator for GFR is often used in the clin-
ical setting, but the accuracy is limited in patients. How-
ever, in sheep, renal clearance of endogenous creatinine
may be a relatively adequate measure of GFR [51].
Conclusions
In summary, our data show that TLR4 signaling is import-
ant for the development of septic AKI and that treatment
Figure 7 Electron microscopic images of the glomerular capillaries in sham (A), vehicle-treated (B), and TAK-242-treated (C) animals.
The same images magnified showing glomerular capillaries in sham (D), vehicle-treated (E), and TAK-242-treated (F) animals. Asterisk indicates
endothelial cell swelling, and arrowheads show decreased fenestration of the glomerular endothelium. Bars = 2 μm (A, B, C) and 1 μm (D, E, F).
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http://ccforum.com/content/18/5/488with a TLR4 inhibitor is able to reverse a manifest reduc-
tion in renal function caused by sepsis. Although further
studies are necessary, this suggests that targeting TLR4
may be a potential way to treat AKI caused by Gram-
negative sepsis. Furthermore, in the present model, septic
AKI is not due to hypoperfusion-induced ischemia but ra-
ther an inflammatory reaction within the kidney reducing
glomerular filtration. Endothelial swelling in the glomeru-
lus may be a contributing factor for the latter.
Key messages
 Inhibiting Toll-like receptor 4 reverses a manifest
renal dysfunction caused by E. coli sepsis.
 In the present model, septic acute kidney injury
is not due to hypoperfusion-induced ischemia
but rather an inflammatory reaction within
the kidney. Endothelial swelling in the glomerulus may be a
contributing factor for the reduced glomerular
filtration.
 Toll-like receptor 4 antagonism has no obvious
effects on renal function in healthy individuals.Additional files
Additional file 1: Detailed Materials and Methods. A more extensive
description of materials and methods.
Additional file 2: Table S3. Sham-operated animal without sepsis.
Data are for sham animal without sepsis (n = 1) and expressed as raw
data from baseline to 36 hours. CI, cardiac index; cort, cortex; Crea
clearance, creatinine clearance; HR, heart rate; Lactateart, arterial levels of
lactate; LD, laser Doppler; L/P, Lactate/Pyruvate ratio; MAP, mean arterial
pressure; med, medulla; MD, microdialysis; MPAP, mean pulmonary
arterial pressure; pCO2, partial pressure of carbon dioxide; pO2, partial
pressure of oxygen; P-Protein, plasma protein; RBF, renal blood flow.
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http://ccforum.com/content/18/5/488Additional file 3: Table S1. Systemic variables. Data are for TAK-242 and
control expressed as mean and standard deviation (SD). Asterisk indicates a
significant difference between TAK-242 and control in response to sepsis.
Analysis of variance (ANOVA) repeated measures, including 12, 18, 24, 30,
and 36 hours. Differences were considered significant at P ≤0.05. cGMP,
cyclic guanosine monophosphate; NOx, the sum of nitrite and nitrate
concentration; pCO2, partial pressure of carbon dioxide; pO2, partial pressure
of oxygen; p-protein, plasma protein.
Additional file 4: Figure S1. Fibrin thrombi formation in glomerular
capillaries. Fibrin thrombi formation in glomerular capillaries. In two of
the vehicle-treated animals, fibrin thrombi (arrow) were seen both in light
microscopy with Ladewig staining (a) and in electron microscopy (b).
Additional file 5: Table S2. Microdialysis in renal cortex and medulla.
Data are for TAK-242 and control expressed as mean and standard
deviation (SD). Asterisk indicates a significant difference between
TAK-242 and control in response to sepsis. Analysis of variance (ANOVA)
repeated measures, including 12, 18, 24, 30, and 36 hours. Differences
were considered significant at P ≤0.05. cort, cortex; MD, microdialysis;
med, medulla.
Additional file 6: Figure S2. Changes in heart rate (A), cardiac index
(B), mean pulmonary artery pressure (MPAP) (C), and mean arterial
pressure (MAP) (D) in response to treatment with either the selective
TLR4 inhibitor TAK-242 (filled symbols) or vehicle (open symbols). N = 3 in
a cross-over design. Data are shown for each individual animal.
Additional file 7: Figure S3. Changes in creatinine clearance (A),
P-creatinine (B), blood urea nitrogen (BUN) (C), renal blood flow (D), and
urine output (E) in response to treatment with either the selective TLR4
inhibitor TAK-242 (filled symbols) or vehicle (open symbols). N = 3 in a
cross-over design. Data are shown for each individual animal.
Additional file 8: Table S4. Sheep without sepsis treated with TAK-242.
Blood gas data for three healthy sheep receiving TAK-242 or vehicle for
12 hours in a cross-over design.
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